Prediction of Alzheimer's disease using midregional proadrenomedullin and midregional proatrial natriuretic peptide / Katharina Buerger en The Journal of Clinical Psychiatry, Año 2011 - Vol.72 - No. 4 (Abril)

Público ISBD [artículo]  inThe Journal of Clinical Psychiatry > Año 2011 - Vol.72 - No. 4 (Abril) . - pp. 556-563 Título : Prediction of Alzheimer's disease using midregional proadrenomedullin and midregional proatrial natriuretic peptide : a retrospective analysis of 134 patients with mild cognitive impairment Tipo de documento: texto impreso Autores: Katharina Buerger, Autor ; Olga Uspenskaya, Autor ; Oliver Hartmann, Autor Fecha de publicación: 2022 Artículo en la página: pp. 556-563 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Enfermedad de Alzheimer, Biomarcadores, Trastornos cognitivos, Enfermedad progresiva. Resumen: Development of biomarkers for early detection of Alzheimer's disease (AD) is a major clinical research goal. On the basis of the hypothesis that cardiovascular risk factors contribute to the pathogenesis of AD, we investigated whether the cardiovascular risk markers midregional proadrenomedullin (MR-proADM) and midregional proatrial natriuretic peptide (MR-proANP) predict a major clinical milestone, ie, conversion from predementia mild cognitive impairment (MCI) to manifest AD. Link: ./index.php?lvl=notice_display&id=27984 [artículo] Prediction of Alzheimer's disease using midregional proadrenomedullin and midregional proatrial natriuretic peptide : a retrospective analysis of 134 patients with mild cognitive impairment [texto impreso] / Katharina Buerger, Autor ; Olga Uspenskaya, Autor ; Oliver Hartmann, Autor . - 2022 . - pp. 556-563. Idioma : Inglés (eng) Idioma original : Inglés (eng) in The Journal of Clinical Psychiatry > Año 2011 - Vol.72 - No. 4 (Abril) . - pp. 556-563 Palabras clave: Enfermedad de Alzheimer, Biomarcadores, Trastornos cognitivos, Enfermedad progresiva. Resumen: Development of biomarkers for early detection of Alzheimer's disease (AD) is a major clinical research goal. On the basis of the hypothesis that cardiovascular risk factors contribute to the pathogenesis of AD, we investigated whether the cardiovascular risk markers midregional proadrenomedullin (MR-proADM) and midregional proatrial natriuretic peptide (MR-proANP) predict a major clinical milestone, ie, conversion from predementia mild cognitive impairment (MCI) to manifest AD. Link: ./index.php?lvl=notice_display&id=27984

---

1 (1 - 1 / 1)